News

Korro to Participate in Upcoming Investor and Scientific Conferences

  • CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:
    09/02/2025

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

  • — Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD)  cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro's rare metabolic disorder program will be announced by end of 2025 — Ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities   CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2025 and provided a business update.
    08/12/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Korro Bio, Inc. (KRRO) can sell. Click on Rating Page for detail.

The price of Korro Bio, Inc. (KRRO) is 31.5358 and it was updated on 2025-09-12 11:00:23.

Currently Korro Bio, Inc. (KRRO) is in overvalued.

News
    
News

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

  • CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
    Mon, Jul. 21, 2025

Korro to Participate in Upcoming Investor Conferences

  • CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram Aiyar, Ph.D.
    Wed, May. 14, 2025

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update.
    Wed, May. 07, 2025

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

  • Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer
    Tue, Apr. 01, 2025

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported full-year 2024 financial results, and provided an update on recent progress and anticipated milestones.
    Tue, Mar. 18, 2025
SEC Filings
SEC Filings

Korro Bio, Inc. (KRRO) - SCHEDULE 13G/A

  • SEC Filings
  • 08/14/2025

Korro Bio, Inc. (KRRO) - SCHEDULE 13G/A

  • SEC Filings
  • 08/13/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 08/12/2025

Korro Bio, Inc. (KRRO) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/12/2025

Korro Bio, Inc. (KRRO) - 8-K/A - Current report

  • SEC Filings
  • 06/18/2025

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 06/12/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 06/11/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 05/07/2025

Korro Bio, Inc. (KRRO) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/07/2025

Korro Bio, Inc. (KRRO) - DEFA14A

  • SEC Filings
  • 04/29/2025

Korro Bio, Inc. (KRRO) - DEF 14A

  • SEC Filings
  • 04/29/2025

Korro Bio, Inc. (KRRO) - ARS

  • SEC Filings
  • 04/29/2025

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 04/01/2025

Korro Bio, Inc. (KRRO) - 3

  • SEC Filings
  • 04/01/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 03/27/2025

Korro Bio, Inc. (KRRO) - S-8

  • SEC Filings
  • 03/18/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 03/18/2025

Korro Bio, Inc. (KRRO) - 10-K - Current report

  • SEC Filings
  • 03/18/2025

Korro Bio, Inc. (KRRO) - SCHEDULE 13G/A

  • SEC Filings
  • 02/14/2025

Korro Bio, Inc. (KRRO) - SCHEDULE 13G

  • SEC Filings
  • 02/14/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 02/11/2025

Korro Bio, Inc. (KRRO) - 3

  • SEC Filings
  • 02/11/2025

Korro Bio, Inc. (KRRO) - SCHEDULE 13G

  • SEC Filings
  • 02/05/2025

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 02/05/2025

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 01/13/2025

Korro Bio, Inc. (KRRO) - EFFECT

  • SEC Filings
  • 12/10/2024

Korro Bio, Inc. (KRRO) - EFFECT

  • SEC Filings
  • 12/10/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 12/10/2024

Korro Bio, Inc. (KRRO) - EFFECT

  • SEC Filings
  • 12/09/2024

Korro Bio, Inc. (KRRO) - 424B5

  • SEC Filings
  • 12/06/2024

Korro Bio, Inc. (KRRO) - S-3

  • SEC Filings
  • 12/02/2024

Korro Bio, Inc. (KRRO) - POS AM

  • SEC Filings
  • 12/02/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 11/21/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 11/21/2024

Korro Bio, Inc. (KRRO) - SC 13G/A

  • SEC Filings
  • 11/14/2024

Korro Bio, Inc. (KRRO) - SC 13G/A

  • SEC Filings
  • 11/12/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 11/12/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 11/12/2024

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 11/12/2024

Korro Bio, Inc. (KRRO) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/12/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 11/04/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 11/04/2024

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 10/18/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 09/16/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 09/16/2024

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 09/03/2024

Korro Bio, Inc. (KRRO) - 3

  • SEC Filings
  • 09/03/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 08/28/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 08/28/2024

Korro Bio, Inc. (KRRO) - 4

  • SEC Filings
  • 08/28/2024

Korro Bio, Inc. (KRRO) - 3

  • SEC Filings
  • 08/28/2024

Korro Bio, Inc. (KRRO) - 8-K - Current report

  • SEC Filings
  • 08/13/2024

Korro Bio, Inc. (KRRO) - 424B3

  • SEC Filings
  • 08/13/2024

Korro Bio, Inc. (KRRO) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/13/2024

Korro Bio, Inc. (KRRO) - SC 13G/A

  • SEC Filings
  • 07/12/2024
Press Releases
StockPrice Release

Korro to participate in upcoming investor and scientific conferences

  • 09/02/2025

Korro reports second quarter 2025 financial results and provides business updates

  • 08/12/2025

Korro receives european medicines agency orphan drug designation for krro-110

  • 07/21/2025

Korro to participate in upcoming investor conferences

  • 05/14/2025

Korro reports first quarter 2025 financial results and provides business updates

  • 05/07/2025

Korro appoints biotech industry veteran, loÏc vincent, ph.d., as chief scientific officer

  • 04/01/2025

Korro reports full year 2024 financial results and provides business updates

  • 03/18/2025

Krro-110 receives orphan drug designation from u.s. fda for alpha-1 antitrypsin deficiency

  • 03/14/2025

Korro to present at the td cowen 45th annual health care conference

  • 02/26/2025

Korro to participate in upcoming investor conferences

  • 11/21/2024

Korro receives australian hrec approval and ctn clearance to initiate phase 1/2a clinical study (rewrite) of krro-110 for alpha-1 antitrypsin deficiency

  • 11/21/2024

Korro to present at the jefferies london healthcare conference

  • 11/14/2024

Korro announces regulatory filing for initiation of krro-110 first-in-human study and formation of clinical advisory board

  • 11/04/2024

Korro announces oral and poster presentations at the 20th annual meeting of the oligonucleotide therapeutics society

  • 09/30/2024

Korro to participate in upcoming september investor and scientific conferences

  • 08/27/2024

Korro reports second quarter 2024 financial results and provides business updates

  • 08/13/2024

Korro to participate in upcoming june investor and scientific conferences

  • 05/30/2024

Korro presents additional preclinical data for krro-110 at the american thoracic society 2024 international conference

  • 05/20/2024

Korro reports first quarter 2024 financial results and appointment of kemi olugemo, m.d. as chief medical officer

  • 05/14/2024

Korro announces $70 million private placement

  • 04/18/2024

Korro to participate in upcoming investor conferences

  • 04/01/2024

Korro reports full year 2023 financial results and highlights recent progress

  • 03/26/2024

Korro to present at the td cowen 44th annual health care conference

  • 02/27/2024

Korro bio highlights data for its lead program in alpha-1 antitrypsin deficiency (aatd) and progress across its rna editing portfolio

  • 01/18/2024

Korro to present at the 42nd annual j.p. morgan healthcare conference

  • 01/04/2024

Korro announces selection of its first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (aatd)

  • 12/07/2023
More Headlines
News

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

  • CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
  • 03/14/2025

Korro to Present at the TD Cowen 45th Annual Health Care Conference

  • CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.
  • 02/26/2025

Korro to Participate in Upcoming Investor Conferences

  • CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
  • 11/21/2024

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

  • -REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
  • 11/21/2024

Korro to Present at the Jefferies London Healthcare Conference

  • CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference.
  • 11/14/2024

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

  • -Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC)
  • 11/04/2024

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.

  • Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.
  • 10/21/2024

Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet

  • The consensus price target hints at a 239.5% upside potential for Korro Bio, Inc. (KRRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  • 10/16/2024

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

  • CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.
  • 09/30/2024

Korro to Participate in Upcoming September Investor and Scientific Conferences

  • CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences:
  • 08/27/2024

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2024 and provided an update on its recent progress and anticipated milestones.
  • 08/13/2024

Korro to Participate in Upcoming June Investor and Scientific Conferences

  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
  • 05/30/2024

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

  • CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) --  Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.
  • 05/20/2024

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

  • On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024
  • 05/14/2024

Korro Announces $70 Million Private Placement

  • CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions.
  • 04/18/2024

Korro to Participate in Upcoming Investor Conferences

  • CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present, and meet investors regarding progress of KRRO-110, Korro's best-in-class candidate for AATD, at the following upcoming investor conferences:
  • 04/01/2024

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

  • CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for the full year ended December 31, 2023, and reiterated its recent progress and anticipated milestones.
  • 03/26/2024

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

  • Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
  • 03/14/2024

Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade

  • The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  • 02/27/2024

Korro to Present at the TD Cowen 44th Annual Health Care Conference

  • CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024, at 2:10 p.m. ET. Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, will also be participating at the conference.
  • 02/27/2024

Best Momentum Stocks to Buy for February 16th

  • Teaser: ECL, CDNS and KRRO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 16, 2023.
  • 02/16/2024

New Strong Buy Stocks for February 16th

  • CDNS, ECL, FMX, KRRO and RMR have been added to the Zacks Rank #1 (Strong Buy) List on February 16, 2024.
  • 02/16/2024

Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?

  • The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  • 02/09/2024

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

  • CAMBRIDGE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, presented new data for KRRO-110 and reported progress across its RNA editing portfolio at the J.P. Morgan Healthcare Conference on January 9, 2024.
  • 01/18/2024

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  • CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 11:15 a.m. PT (2:15 p.m. ET) in the Borgia Room at The Westin St. Francis Hotel in San Francisco. Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will also be participating at the conference.
  • 01/04/2024

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

  • CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant. KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024.
  • 12/07/2023

These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

  • Korro Bio is working on an RNA-editing platform, and its stock price shot up 171% in November. Gyre Therapeutics is a commercial-stage drugmaker in China that could expand into the lucrative U.S. market.
  • 12/02/2023
Unlock
KRRO Ratings Summary
KRRO Quant Ranking